Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Perspective Therapeutics, Inc. Common Stock (NY:CATX)

4.860 +1.000 (+25.91%)
Official Closing Price Updated: 4:10 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Perspective Therapeutics, Inc. Common Stock

< Previous 1 2 3 Next >
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Which stocks are experiencing notable movement on Friday?
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) Surpasses Q2 2025 Revenue Estimates with Narrower Loss
Perspective Therapeutics Inc (CATX) reported strong Q2 2025 revenue, beating estimates by 84%, with a narrower-than-expected loss. The company advances its radiopharmaceutical pipeline, including... 
Via Chartmill
Perspective Therapeutics Reports Q2 Loss
Via The Motley Fool
Topics Economy
A Look Ahead: Perspective Therapeutics's Earnings Forecast
 
Via Benzinga
What's going on in today's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Earnings Scheduled For August 13, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 26, 2025
 
Via Benzinga
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets. 
Via Benzinga
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars
Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, and anti-tumor activity. 
Via Benzinga
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
S&P 500 Moves Higher; BlackRock Reports Upbeat Results
 
Via Benzinga
Topics Stocks
Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals. 
Via Benzinga
Dow Surges 150 Points; JPMorgan Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
CATX Stock Earnings: Perspective Therapeutics Beats EPS, Beats Revenue for Q2 2024
CATX stock results show that Perspective Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Outperforming Stocks Surpassing Even Nvidia This Year
Given its performance in 2024, there are very few stocks outperforming Nvidia this year. Here are three of them. 
Via InvestorPlace
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.